Healthcare >> CEO Interviews >> January 13, 2000
HOLLINGS C. RENTON was appointed Chairman of the Board of Onyx
Pharmaceuticals in June 2000, where he has served as President and Chief
Executive Officer since joining the company in March 1993. Prior to
Onyx, Mr. Renton was President and Chief Operating Officer of Chiron
Corporation. He assumed that position in 1991 on Chiron's acquisition of
Cetus Corporation, where he had been President since 1990 and Chief
Operating Officer since 1987. He holds an MBA from the University of
Michigan. Mr. Renton serves as a member of the board of Cepheid, Rigel
Pharmaceuticals, Inc., the Biotechnology Industry Organization (BIO) and
Special Olympics Northern California. Profile
Mr. Renton: Onyx is focused on developing novel cancer therapies,
particularly around the genetic mutations that cause
